The role of the laboratory in the diagnosis of the metabolic syndrome

American Journal of Clinical Pathology

Volumn 132, Issue 2, 2009, Pages 161-162

  Jialal, Ishwarlal ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN B; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; RETINOL BINDING PROTEIN 4; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; AMINOTRANSFERASE BLOOD LEVEL; ATHEROGENESIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DYSLIPIDEMIA; EDITORIAL; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; INSULIN RESISTANCE; INTERNATIONAL CLASSIFICATION OF DISEASES; LABORATORY DIAGNOSIS; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; MICROALBUMINURIA; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

HUMANS; LABORATORIES; LABORATORY TECHNIQUES AND PROCEDURES; METABOLIC SYNDROME X; PATHOLOGY, CLINICAL;

EID: 68549136813     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCP1B0DHHSAIJJR     Document Type: Editorial

References (10)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA. 2001;285:2486-2497.
2. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735-2752.
3. Jialal I. Editorial. Metab Syndr Relat Disord. 2007;5:1-2.
4. Barter PJ, Ballantyne CM, Carmena R, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med. 2006;259:247-258.
5. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk. J Am Coll Cardiol. 2008;51:1512-1524.
6. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation. 2003;107:391-397.
7. Devaraj S, Rosenson RS, Jialal I. Metabolic syndrome: an appraisal of the pro-inflammatory, procoagulant status. Endocrinol Metab Clin North Am. 2004;33:431-453.
8. Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol. 2009;20:182-189.
9. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes. 2006;55:1537-1545.
10. Devaraj S, Swarbrick M, Singh U, et al. CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Am J Clin Pathol. 2008;129:815-822.